The European Union has issued the CE mark of approval to GI Dynamics of Lexington, MA for its EndoBarrier device as a treatment option for obesity and type 2 diabetes. The device, which is implanted endoscopically via the mouth, essentially creates a chamber in the stomach and effectively limits the amount of food a patient can digest. The device is not intended for permanent placement and the approval stipulates its use for a six month therapeutic period.
Press release: GI Dynamics Receives European CE Mark Approval for the EndoBarrier Gastrointestinal Liner System for the Treatment of Type 2 Diabetes and Obesity…
Flashback: EndoBarrier May Be Helpful in Patients With Type II Diabetes; EndoBarrier, an Internal Condom, Gets Positive Results in Diabetic Clinical Trial; Eat Away, Just Don’t Digest